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Lead-binding proteins are a series of low molecular weight proteins, analogous to metallothionein, which segregate lead in a
nontoxic form in several organs (kidney, brain, lung, liver, erythrocyte). Whether the lead-binding proteins in every organ are
identical or diﬀerent remains to be determined. In the erythrocyte, delta-aminolevulinic acid dehydratase (ALAD) isoforms have
commanded the greatest attention as proteins and enzymes that are both inhibitable and inducible by lead. ALAD-2, although it
binds lead to a greater degree than ALAD-1, appears to bind lead in a less toxic form. What may be of greater signiﬁcance is that
a low molecular weight lead-binding protein, approximately 10 kDa, appears in the erythrocyte once blood lead exceeds 39μg/dL
andeventuallysurpassesthelead-bindingcapacityofALAD.Inbrainandkidneyofenvironmentallyexposedhumansandanimals,
a cytoplasmic lead-binding protein has been identiﬁed as thymosin β4, a 5kDa protein. In kidney, but not brain, another lead-
binding protein has been identiﬁed as acyl-CoA binding protein, a 9kDa protein. Each of these proteins, when coincubated with
liver ALAD and titrated with lead, diminishes the inhibition of ALAD by lead, verifying their ability to segregate lead in a nontoxic
form.
1.Introduction
This paper focuses on lead-binding proteins, which, in
contrast to the majority of articles in this issue, are not toxic
compounds but rather low molecular weight proteins which
have the capacity to bind lead and to sequester the lead in
a nontoxic form. In the discussion which follows, careful
note should be taken as to which lead-binding proteins are
inducible, that is, increased in concentration after exposure
to lead, and which are constitutive, that is, are present
within the organism at all times and may have binding
sites saturable by lead but no discernible increase in protein
content. The second situation is perhaps most pertinent
to enzymes inhibitable by lead, the ﬁrst to proteins not
normallypresentorpresentinlowquantitiesintheorganism
but which increase after lead exposure and oﬀer protection
against lead toxicity. The history of lead-binding proteins
can be dated back to 1936, when Blackman ﬁrst described
the presence of intranuclear inclusion bodies in the liver
and kidney as manifestations of lead poisoning [1]. The
next phase in this saga consisted of detailed studies of the
composition of renal tubular intranuclear inclusion bodies
and the consequent alterations in mitochondrial structure
and function which followed, ﬁrst by Goyer and colleagues,
later by Shelton et al. [2–5], and Klann and Shelton [6, 7].
2. Lead-Binding ProteinswithinIntranuclear
Inclusion Bodies in Kidney
Goyer [8] began his studies by examining the renal tubules
of rats fed 1% lead acetate for up to 20 weeks, ﬁnding that
dense, deeply staining intranuclear inclusions were located
in the straight portion of the proximal tubules, accompanied
by swollen, globular, or ovoid, closely packed mitochondria
withmanymarginated,irregular,orvesicularcristae.Accom-
panying these mitochondrial changes was the presence of
generalized aminoaciduria. In a subsequent paper in the
same issue, Goyer and colleagues [9] isolated mitochondria
from lead-exposed and control rats and demonstrated that
mitochondria from the lead-exposed rats show reduced rates
of respiration and oxidative phosphorylation.2 Journal of Toxicology
Lead within the kidneys in lead-poisoned rats was found
to be concentrated in the nuclei and within nuclei in the
nuclear inclusion body [10, 11]. Choie and Richter [12]
showed further that rapid induction of inclusion bodies by
injections of lead salts in the rat resulted in cytoplasmic
inclusions, suggesting that they were precursors to the
intranuclear inclusions. This was further conﬁrmed by
McLachlin et al. [13] who showed in tissue culture studies
of rat kidney cells incubated with lead that the cytoplasmic
inclusion bodies preceded and disappeared shortly after the
appearance of nuclear inclusion bodies.
Lead-containing nuclear inclusions were also found in
organs other than the kidney, including liver and glial cells of
the central nervous system [14]. Moore et al. [15] dissolved
the rat renal intranuclear inclusions in strong denaturing
agents and found that the protein in the inclusions is acidic,
with high levels of aspartic acid, glutamic acid, glycine and
cystine.MooreandGoyer[16]latercharacterizedtheprotein
as a 27.5kDa protein, which migrates as a single band
on acrylamide gel electrophoresis. Repeated intraperitoneal
injections of calcium disodium ethylenediamine tetraacetic
acid (CaNa2EDTA) resulted in disappearance of the inclu-
sion bodies in lead-exposed rats, together with a marked
decrease in kidney lead levels [17].
Shelton and coworkers have also explored the compo-
sition of the lead-binding proteins in the nuclear inclusion
proteins of lead-exposed rat kidneys. Shelton and Egle [2]
ﬁrst described a 32kDa protein with an isoelectric point of
6.3, which was isolated from the kidneys of rats treated with
1% lead acetate in rat chow or 0.75% lead acetate in drinking
water, given for 13–17 weeks. In contrast to the work
of Goyer and coworkers, they employed two-dimensional
gel electrophoresis to isolate the protein from the nuclear
inclusion bodies and demonstrated that it was present in
lead-exposed, but not control kidneys (hence inducible).
This protein has been termed p32/6.3. Inhibitor studies with
cycloheximide and actinomycin D [13, 18] had indicated
earlier that protein synthesis was required for induction of
the nuclear and cytoplasmic inclusion bodies.
Egle and Shelton [3] then turned their attention to the
brain, where they found unexpectedly that p32/6.3, now
characterized by a monoclonal antibody, was constitutively
present in cerebral cortex, both in neurons and astrocytes.
The protein was concentrated in the insoluble nuclear pro-
tein, similar to the lead-exposed kidney. Brain p32/6.3 was
detected in rat, mouse, dog, man and chicken. In rat brain,
a d u l tl e v e l sw e r ea c h i e v e di n1 - 2w e e k sa f t e rb i r t hw h e r e a s
only trace amounts were found at 3 days. Brain p32/6.3
increases between postnatal days 10–12 in the guinea pig
and days 15–21 in the rat, suggesting that the increase may
be related in part to exposure to the external environment
[5]. When neuroblastoma cells were cultured after 1 and 3
days exposure to lead, the abundance of p32/6.3 increased.
Simultaneous incubation with lead and cycloheximide or
actinomycinDalsoshowedanincreaseinp32/6.3,suggesting
that lead selectively retards the degradation of the brain
protein[6].Theaminoacidcompositionofpartiallypuriﬁed
p32/6.3 revealed a high percentage of glycine, aspartic and
glutamic acid [4]. Thus Shelton and coworkers have estab-
lished that an inducible protein, p32/6.3, can be extracted
from nuclear inclusion bodies from the lead-exposed rat
kidneyandasimilaroridenticalproteinfromadultratbrain.
Whether the brain protein is constitutive or inducible by
exposure to environmental lead has yet to be determined.
Selvin-Testa et al. [19] and Harry et al. [20] reported that
developing rat brain astrocytes exposed to lead developed
an elevation in glial ﬁbrillary acidic protein (GFAP), a
developmentally regulated protein. Harry et al. [20] consider
that the elevated levels of GFAP mRNA during the second
postnatal week after lead exposure may reﬂect the demand
on astrocytes to sequester lead.
Oskarsson and Fowler [21] examined the inﬂuence of
pretreatmentwithleadbyasinglei.p.injectionofleadacetate
(50mg lead per kg body wt) 1, 3 and 6 days before injecting
203Pb. Rats were sacriﬁced 24 hours later and the kidneys
were examined both microscopically and for the distribution
of 203Pb. At 3 days rat, kidneys displayed ﬁbrillar cytoplasmic
inclusions,but,at6daystheseinclusionswerelessprominent
and intranuclear inclusions were observed. 203Pb uptake at 6
days was maximal in the puriﬁed nuclear fraction and in the
nuclear inclusion bodies (7x and 20x control, resp.).
3.Cytoplasmic Lead-Binding Proteinsin
Kidney and Brain
The remaining studies of nonlead-stimulated cytoplasmic
kidney and brain lead-binding proteins have been provided
by Fowler and associates.
Theﬁrststudy[22]reportedonthelead-bindingproteins
in kidney postmitochondrial cytosolic fractions. Binding
of 203Pb was found in two protein fractions of control
kidneys with molecular weights of 11.5 and 63kDa. Binding
was markedly decreased after lead pretreatment. The use
of cadmium to stimulate metallothionein synthesis did not
increase 203Pb binding to the 11.5kDa protein. The two
binding proteins were also present in brain but not in liver
or lung. Subsequently, Mistry et al. [23] demonstrated three
lead-binding proteins (11.5kDa, 63kDa and >200kDa) in
rat kidney cytosol, which had binding characteristics of
high-aﬃnity low-capacity sites with respective Kd values of
13, 40, and 123nM. The 11.5kDa and possibly the 63kDa
protein were capable of translocating lead into the nucleus as
shown by uptake of 203Pb into nuclei incubated with tagged
cytosolic proteins.
Goering and Fowler [24] showed that the 11.5kDa
protein, but not the 63kDa protein, was capable of reversing
lead-induced ALAD inhibition in liver homogenates. This
eﬀect was mediated both by chelation of lead by the lead-
binding protein and by donation of zinc to ALAD [25].
Various divalent metal ions inﬂuence the binding of lead to
the rat kidney cytosolic binding proteins, with an order of
displacement of Cd++ > Zn++ > Pb++.C a ++ had no eﬀect,
while Fe++ had a cooperative eﬀect [26]. These observations
may account for the previously demonstrated eﬀect of
concomitant lead and cadmium administration in reducingJournal of Toxicology 3
total kidney lead [27] and preventing the development of
intranuclear inclusion bodies [28].
More recent studies by Fowler and DuVal [29] identiﬁed
the rat renal lead-binding protein as a cleavage product
of α2-microglobulin, with a Kd of 10−8 Ml e a d .T h e r ea r e
two forms of the protein in the kidney, diﬀerentiated by
the cleavage of the ﬁrst 9 N-terminal residues from the
higher molecular weight form. Other studies by Smith and
coworkers [30] have found two lead-binding proteins in
environmentally exposed human kidneys, identiﬁed as acyl-
CoA-binding protein (ACBP) or diazepan-binding inhibitor
(molecular weight 9kDa) and thymosin β4 (molecular
weight 5kDa). These polypeptides have a high-aﬃnity for
lead (Kd∼14nM).
In rat brain, Goering et al. [31] and DuVal and Fowler
[32] explored the eﬀect of environmental lead on lead-
binding proteins and the ability of rat brain lead-binding
proteins to diminish the inhibition of hepatic ALAD by
lead. In the ﬁrst study, a brain protein of 12kDa was
described, in comparison to the kidney lead-binding protein
of 9kDa. Both competitions of lead binding between the
brain lead-binding protein and ALAD and donation of zinc
by the brain protein (shown by 65Zn uptake) were found to
account for the decreased ALAD inhibition. In the second
study the rat brain lead-binding protein was described as
having a molecular weight of 23kDa, with signiﬁcant levels
of glutamic acid, aspartic acid, and cysteine. Polyclonal
antibody to rat renal lead-binding proteins showed a lack of
reactivity with the brain protein, indicating that the proteins
are immunologically distinct.
Fowler et al. [33] examined monkey kidney and brain
from nonlead treated animals and isolated lead-binding
proteins that also had a relatively high content of aspartic
and glutamic amino acid residues and were similar in
size to the rat lead-binding proteins. Polyclonal antibodies
to α2-microglobulin and metallothionein did not cross-
react with either monkey kidney or brain proteins. In
environmentally lead-exposed humans, Quintanilla-Vega et
al. [34] subsequently isolated from brain a thymosin β4a n d
asecond,asyetunidentiﬁed,proteinwithamolecularweight
of 20kDa and a pI of 5.9.
As reported earlier, lead also binds to p32/6.3, a
low-abundance, highly conserved nuclear matrix protein
that becomes a prominent component of lead-induced
intranuclear inclusion bodies [6]. Expression of this protein
increases signiﬁcantly during ontogeny, and was proposed
as an indicator of neuronal maturation [7]. Expression also
increases markedly in the presence of acute lead exposure in
vitro,suggestingthatleadeitherstructurallyalterstheprotein
or inhibits a protease for which p32/6.3 is a substrate [5].
Recently, an astroglial glucose-regulated protein
(GRP78) has been identiﬁed that acts as a molecular
chaperone in endoplasmic reticulum [35, 36]. Intracellular
levels of this protein are increased in cultured astroglia
during a 1-week exposure to lead. GRP78 depletion
significantly increased the sensitivity of cultured glioma cells
to lead, as indicated by the generation of reactive oxygen
species. This suggests that GRP78 is a component of
the intracellular tolerance mechanism that handles high
intracellular lead accumulation. Thus it appears that lead
directly targets the protein, enabling it to play a protective
role in lead neurotoxicity. The generation of reactive oxygen
species also has been reported to occur via lead binding
to astroglial copper-transporting ATPase, resulting in
disruption in copper homeostasis [37].
4.Lead-BindingProteinsinErythrocytes
Intraerythrocytic lead binding was initially attributed pri-
marilytohemoglobin,molecularweight64kDa[38–41],but
more recent studies have ascribed the major lead binding
to delta-aminolevulinic acid dehydratase (ALAD), molecular
weight 240kDa (vide infra), which is an important step in
heme biosynthesis [42]. In contrast to this protein, several
studies have focused on an inducible low molecular weight
protein which appears in workers chronically exposed to
lead and which seems to have a protective eﬀect. The ﬁrst
recognition of this protein was by Raghavan and Gonick [41]
who found an approximately 10kDa protein in lead workers
but not in controls following Sephadex G-75 fractionation.
Upon subsequent SDS-polyacrylamide gel electrophoresis,
theproteinsplitintotwobands,onlytheuppermostofwhich
containedlead.Raghavanetal.[43]thenwentontofraction-
atetheerythrocyteleadintoa“hemoglobin”fraction,10kDa
fraction, free lead, and a “residual lead” fraction, thought
to be composed of membrane lead and a high molecular
weight fraction. Lead workers manifesting toxicity at both
high blood lead and relatively low blood lead levels showed
high levels of residual lead, attributed in the workers with
toxicity at low blood lead levels to a very low quantity of the
10kDa fraction. In a follow-up paper, Raghavan et al. [44]
found elevated levels of lead in the high molecular weight
fraction (prehemoglobin) and in the membrane fraction in
workers with toxicity at both high and low blood leads.
Again, those with toxicity at low blood lead had low levels
of the lead bound to the 10kDa protein. Membrane lead was
found to correlate inversely with membrane Na-K-ATPase;
no correlation was seen with total blood lead. Gonick et al.
[45] partially puriﬁed the 10kDa protein by HPLC using a
protein I-125 column, followed by isoelectric focusing on a
sucrose gradient column. Three protein peaks resulted, one
of 30kDa, and two of approximately10kDa. Only one of the
latter peaks contained lead. This peak had a pI of 5.3 and a
molecular weight, determined by SDS-PAGE, of 12kDa. The
majorityofleadwasfoundinthispeak,whichalsocontained
calcium, zinc, and cadmium. Amino acid analysis showed a
very high percentage of glycine (44%), lower quantities of
histidine, aspartate, and leucine. The presence of glycine and
aspartate corresponds in part to the composition of amino
acids in the intranuclear inclusion bodies, as described by
Shelton et al. [4] and Moore et al. [15].
Ong and Lee [40] studied the distribution of 203Pb in
components of normal human blood. Ninety-four percent4 Journal of Toxicology
of 203Pb was incorporated into the erythrocyte, and 6%
remained in the plasma. SDS-PAGE of plasma showed that
90% was present in the albumin fraction. Within the ery-
throcyte membrane the most important binding site was the
high molecular weight fraction, about 130–230 kDa. Within
the erythrocytic cytoplasm the protein band associated with
203Pb had a molecular weight of 67kDa as shown by the
elution characteristics on G-75 chromatography. This was
thought to be hemoglobin. Lolin and O’Gorman [39]a n d
Church et al. [46, 47], following the same procedure as
Raghavan and Gonick [41], conﬁrmed the ﬁndings of a low
molecular weight protein in the erythrocytes of lead workers,
not found in control patients. Lolin and O’Gorman [39]
quantitated the protein, which ranged from 8.2 to 52.2mg/L
RBC in lead workers but none in controls, again implying an
inducible protein. They found that the low molecular weight
protein ﬁrst appeared when the blood lead concentration
exceeded 39μg/dL. A positive correlation was seen between
the amount of the intraerythrocytic low molecular weight
protein and dithiothreitol-activated activity (i.e., “restored”
ALAD activity) but not the nonactivated activity. Church
et al. [46, 47] also conﬁrmed the ﬁndings of Raghavan
and Gonick [41]. In the initial paper, they described two
patients with high blood lead levels, an asymptomatic
worker with a blood lead of 180μg/dL and a symptomatic
worker with a blood lead of 161μg/dL. In the ﬁrst patient,
approximately 67% of the erythrocyte lead was bound to
a low molecular weight protein of approximately 6-7kDa.
In the second patient, the protein only contained 22% of
the total erythrocytic lead. In their remaining paper [47],
Church et al found that a sample of the low molecular weight
protein puriﬁed from lead workers, which they termed
protein M, had characteristics of metallothionein, such as a
molecular weight of 6.5kDa, a pI between 4.7 and 4.9 and
a greater UV absorbance at 254nm than at 280nm. Amino
acid composition showed 33% cysteine but no aromatic
amino acids. This composition diﬀered from that of the
low molecular weight protein described by Gonick et al.
[45], which had a molecular weight of 12kDa, a pI of 5.3,
and amino acid analysis which showed no cysteine. This
discrepancy might be explained by a combined lead and
cadmium exposure in the Church et al. study, which may
have produced a lead-thionein (vide infra).
Xieetal.[48]usedaBiogelAcolumninsteadofSephadex
G-75 to separate lead-binding proteins from erythrocyte
hemolysates from a control patient and from lead-exposed
workers. In this study they showed clearly that the major
lead-binding occurred to a large molecular weight protein,
consistent with ALAD, in both the controls and leadworkers.
When they added increasing amounts of lead to the blood
of the control patient, a second, low molecular weight, lead-
binding peak occurred which became larger than the lead
binding to the ALAD peak when the lead concentration
exceeded approximately 50μg/dL. This second peak was also
seen in a chronically lead-exposed worker, and was estimated
tobelessthan30kDainmolecularweight.Thustheseresults
are consistent with the aforementioned studies.
5. Is ALADan InducibleEnzyme andIs It
the PrincipalLead-BindingProteininthe
Erythrocyte?
The enzyme ALAD has been found to be the most sensitive
indicator of lead exposure and toxicity [49, 50]. In the
1980’s, two articles were presented which appear to show
that ALAD is inducible after lead exposure in humans.
By comparing a nonexposed control population to lead
workers, and assaying ALAD by means of immunoassay
or as “restored” ALAD activity (i.e., incubation with heat,
zinc and dithiothreitol), both articles indicated that the
amount of ALAD, as contrasted to ALAD activity,w a s
increased by lead exposure [51, 52]. Similar ﬁndings were
reported for the rat [53]. Subsequent studies have focused
on the eﬀect of ALAD polymorphism on the susceptibility
to lead intoxication. ALAD is a zinc-containing enzyme,
which catalyzes the second step of heme synthesis, that is,
catalyzes the condensation of two delta-aminolevulinic acid
molecules into one molecule of porphobilinogen [51]. It is
a polymorphic protein with three isoforms: ALAD-1, ALAD
1-2, and ALAD 2-2. Several studies have shown that, with
the same exposure to lead, individuals with the ALAD-2
gene have higher blood lead levels [54–60]. Initially it was
thought that these individuals might be more susceptible to
leadpoisoning[59],butitisnowappreciatedthattheALAD-
2g e n eo ﬀers protection against lead poisoning by binding
lead more securely [61]. It has been shown that ALAD-2
is more electronegative than ALAD-1 and thus the ALAD-
2 enzyme may have a higher aﬃnity/stability for lead than
ALAD-1[62].Insupportofthisstatementitcanbecitedthat
individuals with the ALAD 1-2/2-2 genotypes in comparison
to those with ALAD 1-1 genotypes have not only higher
blood lead but also decreased plasma aminolevulinic acid
[63], lower zinc protoporphyrin [56], lower cortical bone
lead [58], and lower amounts of dimercaptosuccinic-acid
(DMSA-) chelatable lead [64].
The signiﬁcance of erythrocyte ALAD lead-binding was
initially conﬁrmed by a study by Bergdahl et al. [55], in
which the authors used a FPLC Superdex 200 HR 10/30
chromatographic column coupled to ICP-MS (for determi-
nation of lead) to examine erythrocytes from lead workers
and controls. They found the principal lead-binding protein
peak to be of 240kDa, rather than the presumed hemoglobin
peak reported by Barltrop and Smith [38] and Raghavan and
Gonick [41], using Sephadex G-75 chromatography. This
was shown to be ALAD by binding to speciﬁc ALAD anti-
bodies. Two additional smaller lead-binding peaks of 45kDa
and 10kDa were also seen, but not identiﬁed. Bergdahl et
al. [55] attributed the discrepancies in the studies to the fact
that Sephadex G-75 separates proteins in the range of 3 to
80kDa, making the separation of hemoglobin (molecular
weight64kDa)fromALAD(molecularweight240–280kDa)
very diﬃcult. In addition, the earlier studies had utilized
binding of 203Pb or 210Pb to identify the binding proteins,
a technique which may have skewed the ﬁndings if ALADJournal of Toxicology 5
were already saturated with lead. ALAD-binding capacity
for lead has been measured at 85μg/dL in erythrocytes or
40μg/dl in whole blood [65], which would permit a greater
degree of binding to the low molecular weight component
when blood lead exceeded 40μg / d L .B e r g d a h le ta l .[ 65]h a v e
speculated that the low molecular weight component might
be acyl-CoA-binding protein, identical to the kidney lead-
binding protein described by Smith et al. [30]. Goering and
Fowler [66] had reported earlier that the presence of low
molecular weight high-aﬃnity (Kd 10−8 M) lead-binding
proteins in kidney and brain served as protection against
ALAD inhibition in those organs, whereas the absence of
these low molecular weight proteins in liver contributed to
the greater sensitivity to ALAD inhibition in that organ.
6. Lead-Binding ProteinsinRat Liver
Sabbioni and Marafante [67] explored the distribution of
203Pb in rat whole tissue as well as in subcellular fractions
of liver. By far the largest quantity of lead recovered was in
the kidney, with lesser amounts in liver, spleen, and blood.
Upon subcellular fractionation of the liver, the majority of
203Pb was found in the nuclei, and most of the lead was
detectedinthenuclearmembranefractionboundexclusively
to membrane proteins. The intranuclear lead was associated
with histone fractions. As we have seen previously from
Oskarsson et al. [22], lead-binding proteins were not found
in the cytoplasm of the liver.
7.Lead-Binding ProteinsinIntestine
Fullmer et al. [68] have shown in the chick and cow that
althoughleaddoesnotstimulatelead-bindingproteinsinthe
intestine directly, lead can displace calcium from calcium-
binding proteins, and thus calcium-binding proteins may
play a role in intestinal lead transport. Puriﬁed calcium-
binding protein from chick and cow, as well as calmodulin,
troponin C, and oncomodulin, was dialyzed against added
labelled and unlabelled lead or calcium. Results disclosed
high-aﬃnity binding sites, greater for lead than for calcium.
Similar results were obtained with calmodulin, troponin C,
and oncomodulin members of the troponin C super family
of calcium-binding proteins.
8.Lead-Binding ProteinsinLung
Singh et al. [69] described intracellular lead-inclusion bodies
in normal human lung small-airway epithelial cells cultured
with either lead chromate particles or sodium chromate.
Cells exposed to both forms of chromate underwent dose-
dependent apoptosis. Lead-inclusion bodies were found in
nucleus and cytoplasm of lead chromate, but not sodium
chromate, treated cells. Lead, but not chromium, was
detected in the inclusion bodies by energy dispersive X-ray
analysis. The protein within the inclusion bodies has not
been analyzed.
9. Relationship of Lead-Binding
ProteintoMetallothionein
Similarities of lead-binding protein to metallothionein have
been discussed earlier. Maitani et al. [70] commented that
hepatic zinc metallothionein could be induced by intra-
venous intraperitoneal injections of lead into mice, but not
by subcutaneous injection. Ikebuchi et al. [71] found that
a sublethal dose of lead acetate injected intraperitoneally
into rats induced the synthesis of a lead metallothionein in
addition to zinc metallothionein. The lead metallothionein
contained 28% half cysteine and cross-reacted with an
antibody against rat zinc-thionein II.
Goering and Fowler [66, 72] demonstrated that pre-
treatment of rats with zinc 48 and 24hrs prior to injection
of 203Pb resulted in both zinc and lead coeluting with
a zinc-thionein fraction on Sephadex G-75 ﬁltration. In
addition, both puriﬁed zinc-thionein-I and II bound 203Pb
in vitro. Gel ﬁltration of incubates containing liver ALAD
and 203Pb demonstrated that the presence of zinc-thionein
alters the cytosolic-binding pattern of lead, with less bound
to ALAD. Zinc-thionein also donates zinc to activate ALAD.
In the second paper [66], Goering and Fowler found that
pretreatment of rats with either cadmium or zinc aﬀected
liver ALAD activity when incubated with lead. Liver and
kidney zinc-thioneins, and to a lesser extent, cadmium-zinc-
thionein decreased the free pool of lead available to interact
with ALAD, resulting in attenuated ALAD inhibition. Liu et
al. [73] further showed that zinc-induced metallothionein
in primary hepatocyte cultures protects against lead-induced
cytotoxicity, as assessed by enzyme leakage and loss of
intracellular potassium.
Qu et al. [74] and Waalkes et al. [75] have shown that
metallothionein-null phenotypic mice are more susceptible
to lead injury over a 20-week period than wild-type mice.
Unlike the wild-type mice, lead-treated metallothionein-null
mice showed nephromegaly and signiﬁcantly decreased renal
function after exposure to lead. The metallothionein-null
mice accumulated less renal lead than wild-type and formed
no inclusion bodies. When the observations were extended
to 104 weeks, renal proliferative lesions (adenoma and cystic
tubular atypical hyperplasia) were more common and severe
in metallothionein-null than in wild-type mice. A metastatic
renal cell carcinoma occurred in a metallothionein-null
mouse whereas none occurred in wild-type mice. Such
studies lend credence to the view that metallothionein or
a closely related gene is involved in the formation of lead-
binding proteins in the kidney.
Am o r er e c e n ts t u d y[ 76] further supports the involve-
ment of metallothionein in lead-induced inclusion body
formation. Immunochemical studies revealed that metal-
lothionein could be detected on the outer surface of lead-
induced renal inclusion bodies in wild-type mice. Cell
lines from metallothionein-null and wild-type mice were
exposed to lead, resulting in inclusion body formation in
the wild-type, but not the metallothionein-null cells. When
metallothionein was transfected into the metallothionein-
null cells, inclusion bodies were seen. Further studies
revealed that α-Synuclein, an aggresomal protein, showed6 Journal of Toxicology
poorbasalexpressioninmetallothionein-nullcellsandfailed
to increase after lead exposure, but increased rapidly in wild-
typecells,thendecreasedafterinclusionbodieswereformed.
An antibody pulldown assay conﬁrmed a direct interaction
between α-Synuclein and metallothionein as the proteins
coprecipitated with an antibody to metallothionein.
10. Biochemical Studies of Metal
BindingtoProteins
Three important papers have appeared concerning the
mechanism by which a metal ligand binds to proteins. Lead
is known to displace physiologically relative metal ions, such
as calcium and zinc, in proteins. Kirberger and Yang [77]
reported that approximately 1/3 of the lead binding sites
were identiﬁed as due to zinc or calcium ionic displacement,
whereas two-thirds were opportunistic. Oxygen atoms from
amino acids or water represent the major ligand for lead, fol-
lowed by sulfur and nitrogen. Sulfur acts as the ligand in the
case of displacement of zinc by lead at the zinc-binding sites
in delta-aminolevulinic acid dehydratase (ALAD). Studies
of calmodulin, a calcium binding protein with a propensity
for displacement of calcium by lead, showed an initial
activation followed by inhibition in response to increasing
concentrations of lead. The latter was thought to result from
more pronounced conformational changes resulting from
additional opportunistic binding. Hanas et al. [78] explored
whethertheassociationofleadwithchromatinmightsuggest
that the deleterious eﬀects may in part be mediated through
alterations in gene function. They speciﬁcally examined
whether lead altered DNA binding of cysteine-rich zinc
ﬁnger proteins. It was found that inhibition of Cys2His2 zinc
ﬁnger transcription factors by lead ions at concentrations
near those known to have deleterious physiological eﬀects
was suggestive for a new molecular mechanism for lead
toxicity. However, the changes were seen predominantly at
lead concentrations varying from 100 to 400ug/dL, above
the industrial or pathophysiological range. Becker et al. [79]
analyzed naturally occurring metal-binding proteins in rat
liver and kidney, utilizing nondenaturing gel electrophoresis
together with laser ablation inductively coupled plasma mass
spectrometry (LA-ICP-MS). The mass range of proteins
separated was from 45 to 120kDa. Lead was found only in
smallquantitiesinthe65kDaproteinband,whereaszincand
copper were scattered throughout the protein bands. If this
technique could be extended to the study of lead-treated as
well as native rats and the protein mass separated down to
5kDa, conﬁrmation (or lack thereof) of the results reported
earlier by Fowler and associates [22–24, 29, 33]m i g h tb e
anticipated.
11. Discussion
There appears to be a consensus that the enzyme, ALAD,
a 240–280kDa protein, is moderately inducible and is the
major lead-binding protein within the erythrocyte. ALAD
polymorphism inﬂuences the degree of lead binding as the
ALAD-2 phenotype binds more lead in a nontoxic fashion
than ALAD-1. What is more confusing is the nature and
importance of the low molecular weight erythrocytic lead-
binding protein. There is no doubt that it appears in lead-
exposed workers once blood lead exceeds 40μg/dL but does
not appear in controls. An intriguing observation was made
by Xie et al. [48], who noted that the in vitro addition of lead
toerythrocytesofcontrolsresultedintheappearanceofalow
molecular weight lead-binding peak migrating in the same
positionasthelowmolecularweightpeakfromleadworkers.
This suggests that lead can eﬀect a conformational change
in a preexisting protein. The nature of the low molecular
weight protein is also questionable as Gonick and colleagues
[45] identiﬁed it as a 12kDa protein with a high percentage
of glycine, plus histidine, aspartic acid and leucine while
Church and coworkers [46, 47] identiﬁed the protein as a
6.5kDa molecule, with a large percentage of cysteine and a
greater UV absorbance at 254 than 280nm. These ﬁndings
suggested to the latter authors that the protein might be a
metallothionein.
Metallothionein is a protein that is mildly inducible by
l e a d ,b u tt oam u c hg r e a t e rd e g r e eb yz i n ca n dc a d m i u m .
What is more signiﬁcant is that lead binds to preformed
metallothionein, stimulated by zinc or cadmium, so that
under these conditions a lead-thionein is formed. If con-
comitant lead and cadmium exposure occurred in the lead
workers described by Church et al. [46, 47], that could
reasonably account for the ﬁnding of metallothionein in
these workers. However the possible role of metallothionein
as a component of the renal lead-binding protein seems
more likely as metallothionein-null mice failed to respond
to lead exposure by developing intranuclear lead inclusion
bodies, whereas metallothionein-null cells transfected with
metallothionein were capable of responding to lead.
Extensive studies of cytoplasmic lead-binding proteins
in nonlead-treated rats, human, and monkeys have been
reported. Whether these proteins have formed as a result
of environmental exposure to lead or are preformed is at
present unclear. The lead-binding protein in rat kidney has
been identiﬁed as a cleavage product of α2- microglobulin.
The low molecular weight lead-binding proteins in human
kidney have been identiﬁed as thymosin β4 (molecular
weight 5kDa) and acyl-CoA-binding protein (molecular
weight 9kDa). In human brain, the lead-binding proteins
werethymosinβ4andanunidentiﬁedproteinof23kDa.The
principalremainingquestioniswhetherthep32/6.3intranu-
clear lead-binding protein initially described by Shelton and
Egle [2] represents a condensation product from these low
molecular weight proteins.
12. Conclusions
Lead-binding proteins occur in many organs in the body,
including kidney, brain, erythrocyte, liver, and lung. In
most instances, they appear to be of low molecular weight,
inducible by lead exposure, and to aﬀord some protection
against lead toxicity. The exception is the enzyme delta-
aminolevulinic acid dehydratase (ALAD), which is present
in high concentration in the erythrocyte, and althoughJournal of Toxicology 7
further inducible by lead exposure, is exquisitely sensitive to
inhibition by lead.
The relationships between the intranuclear lead-binding
protein of the kidney, the cytoplasmic lead-binding proteins,
and the lead-binding proteins in erythrocytes remain to be
determined. What is clear is that the inducible lead-binding
proteins aﬀord protection against lead toxicity.
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